Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients

Masson, Adèle de; Darbord, Delphine; Dobos, Gábor; Boisson, Margaux; Roelens, Marie; Ram‐Wolff, Caroline; Cassius, C.; Buanec, Hélène Le; Grange, Pierre de la; Jouenne, Fanélie; Louveau, Baptiste; Sadoux, Aurélie; Bouaziz, Jean‐David; Marie‐Cardine, Anne; Bagot, Martine; Teisserenc, Hélène; Mourah, Samia; Battistella, Maxime

doi:10.1182/blood.2021013341

Cited by 41 publications

(59 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is consistently expressed on the surface of malignant T lymphocytes, the benign T helper type 2 cells and effector regulatory T cells. The occurrence of the granulomatous drug eruption, with increased CD8 T cells, may reflect an increased antitumour response, which is consistent with our clinical observation and previous studies 4,5,7 …”

Section: Figuresupporting

confidence: 92%

See 1 more Smart Citation

Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides

et al. 2022

Self Cite

View full text Add to dashboard Cite

definition of publication was publication of results either in peer-reviewed journals or on ClinicalTrials.gov; our secondary definition was publication in peer-reviewed journals. Variables included in our model (Table 1) were determined a priori.Overall, 141 RCTs met our inclusion criteria. Sixteen RCTs (11%), with 4904 participants, were discontinued prematurely. Reasons included business or sponsor decision (n = 7), insufficient patient recruitment (n = 4) and administration or conduct problems (n = 1). Four RCTs did not provide a reason for discontinuation. Unblinded RCTs (vs. RCTs with blinding of any sort) were significantly more likely to be discontinued (OR 16Á7, 95% CI 2Á22-125) (Table 1).In total, 104 RCTs (74%) met our primary definition of publication, including 93 published in peer-reviewed journals. RCTs investigating topical treatments were significantly more likely to result in nonpublication of results in the multivariable analysis using our primary definition of publication (OR 24Á2, 95% CI 1.14-516) (Table 1), as well as our secondary definition of publication (OR 14Á7, 95% CI 1Á17-185). Discontinued RCTs were associated with nonpublication in the univariable analysis, but this association was attenuated when adjusted for additional factors (OR 4Á50, 95% CI 0Á74-27Á4).In this study of phase III RCTs of psoriasis treatments, 11% of the RCTs were discontinued prematurely, a rate lower than reported in other areas of medicine. [2][3][4] Half of the discontinued RCTs did not cite a reason for discontinuation, and for those that did, the lack of semantic standardization for reasons for discontinuation listed on ClinicalTrials.gov leads to ambiguity and predisposes to misinterpretation. Over a quarter of psoriasis RCTs did not publish their results in peer-reviewed journals or on ClinicalTrials.gov, which is consistent with RCTs in other areas of medicine. 2,3 Topical intervention was the only factor significantly associated with increased nonpublication following adjustment for additional variables. A report on ClinicalTrials.gov for Janus kinase inhibitor therapy suggested that the nonpublication of trials for topical interventions may be related to a lack of efficacy, as many were discontinued due to inefficacy or futility. 5 These findings may also be explained by the increased emphasis in the literature on the evolving systemic treatment landscape.Our study limitations include potential inaccuracies or missing data in trial registry entries, although trial data undergo quality control via automated checks and manual review by ClinicalTrials.gov staff. Our statistical analyses were also limited by the small number of events for certain variables, with inadequate statistical power to assess associations thus limiting interpretation of results.The nonpublication of RCTs of psoriasis remains prevalent. Insight into challenges that prevent RCTs from reaching completion is limited by the lack of reporting of reasons for discontinuation on trial registries. Reporting of reasons for discontinuation on t...

show abstract

Section: Figuresupporting

confidence: 92%

“…Here, we report a retrospective case series of patients seen at our centres since 2013, who had granulomatous rash mimicking MF on photoexposed skin. The incidence of this type of rash in the total cohort of patients with CTCL treated with mogamulizumab at our centres was 6%, and the incidence of MAR, as previously reported, was 32% 5 …”

Section: Figuresupporting

confidence: 85%

Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…FACS analysis was performed according to previous reports [ 64 ]. Briefly, staining of cells for flow cytometry was performed in suspension cell from kidney tissue using between 1 × 10 5 and 1 × 10 6 cells per tube.…”

Section: Methodsmentioning

confidence: 99%

Twist1 regulates macrophage plasticity to promote renal fibrosis through galectin-3

Sun

Wei

et al. 2022

Cell. Mol. Life Sci.

View full text Add to dashboard Cite

Renal interstitial fibrosis is the pathological basis of end-stage renal disease, in which the heterogeneity of macrophages in renal microenvironment plays an important role. However, the molecular mechanisms of macrophage plasticity during renal fibrosis progression remain unclear. In this study, we found for the first time that increased expression of Twist1 in macrophages was significantly associated with the severity of renal fibrosis in IgA nephropathy patients and mice with unilateral ureteral obstruction (UUO). Ablation of Twist1 in macrophages markedly alleviated renal tubular injury and renal fibrosis in UUO mice, accompanied by a lower extent of macrophage infiltration and M2 polarization in the kidney. The knockdown of Twist1 inhibited the chemotaxis and migration of macrophages, at least partially, through the CCL2/CCR2 axis. Twist1 downregulation inhibited M2 macrophage polarization and reduced the secretion of the profibrotic factors Arg-1, MR (CD206), IL-10, and TGF-β. Galectin-3 was decreased in the macrophages of the conditional Twist1-deficient mice, and Twist1 was shown to directly activate galectin-3 transcription. Up-regulation of galectin-3 recovered Twist1-mediated M2 macrophage polarization. In conclusion, Twist1/galectin-3 signaling regulates macrophage plasticity (M2 phenotype) and promotes renal fibrosis. This study could suggest new strategies for delaying kidney fibrosis in patients with chronic kidney disease.

show abstract

“…Accordingly, long‐lasting complete remissions have been associated with autoimmune manifestations in patients with SS treated with MOGA 6–8 . Skin rashes are frequent events, 9–12 associated with long‐term remission 13 . Therefore, MOGA may activate antitumour immunity, while leading to autoimmunity 14 …”

mentioning

confidence: 99%

“…[6][7][8] Skin rashes are frequent events, [9][10][11][12] associated with long-term remission. 13 Therefore, MOGA may activate antitumour immunity, while leading to autoimmunity. 14 Here, we hypothesized that, besides the targeted depletion of CCR4 + malignant cells, MOGA induces substantial immunological changes that could improve long-term clinical response.…”

mentioning

confidence: 99%

Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome*

et al. 2022

Self Cite

View full text Add to dashboard Cite

Summary Background Mogamulizumab, an anti‐CCR4 monoclonal antibody, has been shown to increase progression‐free survival in cutaneous T‐cell lymphoma. Objectives We hypothesized that besides the targeted depletion of Sézary cells (SCs), mogamulizumab may reshape the immune tumour microenvironment. Methods Both malignant and benign compartments from 26 patients with B2 stage Sézary syndrome before mogamulizumab initiation were prospectively analysed using KIR3DL2 and TCRVβ markers, serological markers and molecular assessments of clonality. Results Prior to mogamulizumab, the benign subset of CD4+ T cells displayed exhausted phenotypes, with an increased gradient in programmed death‐1, TIGIT, DNAM‐1, CD27, CD28 and CD70 expression from age‐matched controls to patients’ benign CD4+ T cells and to SCs. All patients presented SCs with heterogeneous phenotypes, and differential expression of individual markers was found within distinct malignant subsets. Early complete blood response was observed in 17 of 26 patients and was associated with higher baseline CCR4 expression. A drastic decrease in benign T cells and activated regulatory T‐cell counts was observed during the first 4 weeks. Long‐term follow‐up revealed the emergence of an immune restoration involving CD8+ and naive and stem memory CD4+ T cells, with almost complete disappearance of exhausted lymphocytes. Development of resistance or tumour escape to mogamulizumab was associated with the emergence of CCR4− SCs in blood and skin, displaying significant changes in their heterogeneity patterns, and not explained only by mutations within CCR4 coding regions. Conclusions Mogamulizumab likely contributes to the restoration of efficient immunity and reshapes not only the malignant lymphocyte subset but also the benign subset. These results have potential implications for optimal therapeutic sequences and/or combinations. What is already known about this topic? Management of Sézary syndrome (SS) involves successive therapies that participate as cause and consequence in the emergence of resistant clones, on a background of immunodeficiency. We and others have reported the complex and dynamic heterogeneity of Sézary cells (SCs) during disease progression. Mogamulizumab therapy, by targeting the skin‐homing receptor CCR4, mainly expressed by SCs, has been shown to increase progression‐free survival in patients with SS. What does this study add? Using multicolour flow cytometry, we provide quantification of CCR4 and immune checkpoint molecules on malignant SCs and benign CD4+ T cells from patients with SS, separated using KIR3DL2 and TCRVβ expression. Mogamulizumab is not only aimed at eradicating malignant SCs but potentially contributes to the restoration of efficient immunity. Tumour escape is associated with the emergence of CCR4− SCs, not explained only by mutations within CCR4 coding regions.

show abstract

Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients

Cited by 41 publications

References 36 publications

Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides

Head and neck granulomatous rash associated with mogamulizumab mimicking mycosis fungoides

Twist1 regulates macrophage plasticity to promote renal fibrosis through galectin-3

Mogamulizumab induces long‐term immune restoration and reshapes tumour heterogeneity in Sézary syndrome*

Contact Info

Product

Resources

About